• Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

    16 days ago - By News Medical

    Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.
    Read more ...

     

  • NeoTract announces results of study measuring costs and patient outcomes of UroLift System

    16 days ago - By News Medical

    NeoTract, a wholly owned subsidiary of Teleflex Incorporated focused on addressing unmet needs in the field of urology, today announced the results of an independent analysis measuring costs and patient outcomes of the UroLift System compared to transurethral resection of the prostate.
    Read more ...